ADM (Archer Daniels Midland Company) has announced a new research partnership with the University of Oxford to study the link between the gut microbiome and emotional and cognitive wellbeing in women during early menopause. The collaboration will involve a clinical trial evaluating the effects of a 14-strain probiotic supplement on mood, cognitive function, and emotional processing in 106 perimenopausal women. This randomized, double-blind, placebo-controlled study aims to deepen understanding of how probiotics may positively affect menopausal symptoms, with headline results expected in spring 2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADM - Archer Daniels Midland Company published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.